<DOC>
	<DOCNO>NCT01650779</DOCNO>
	<brief_summary>This exploratory study evaluate change glycosphingolipid level ( exploratory ) Fabry disease parameter male Fabry disease participant previously treat agalsidase alfa ( Replagal® ) 0.2 milligram per kilogram ( mg/kg ) every two week ( q2w ) switch agalsidase beta ( Fabrazyme® ) 1.0 mg/kg q2w .</brief_summary>
	<brief_title>A Study Evaluating Glycosphingolipid Clearance Patients Treated With Agalsidase Alfa Who Switch Agalsidase Beta</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>The participant and/or parent/legal guardian willing able provide sign informed consent , participant , less ( &lt; ) 18 year age , willing provide assent deem able Participant male treat agalsidase alfa 0.2 mg/kg q2w 12 month prior switch agalsidase beta The participant confirm diagnosis Fabry disease alfagalactosidase A ( alfaGAL ) activity and/or genotyping per local standard The participant switch agalsidase beta receives label dose , , 0.9 1.1 mg/kg ( 1 mg/kg ) q2w , must willing maintain label dose duration study The participant dialysis post renal transplantation The participant endstage cardiac failure The participant and/or parent legal guardian , opinion investigator , unable adhere requirement study The participant switch agalsidase alfa agalsidase beta historical blood urine sample</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>alpha-galactosidase A</keyword>
	<keyword>a-GAL</keyword>
	<keyword>Fabry</keyword>
	<keyword>GL-3</keyword>
	<keyword>Fabrazyme</keyword>
</DOC>